| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Cytokinetics Incorporated (NASDAQ: CYTK)
CYTK Technical Analysis
3
| As on 16th Oct 2025 CYTK STOCK Price closed @ 58.96 and we RECOMMEND Buy for LONG-TERM with Stoploss of 51.94 & Buy for SHORT-TERM with Stoploss of 55.85 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CYTKSTOCK Price
| Open | 62.94 | Change | Price | % |
| High | 63.58 | 1 Day | -3.84 | -6.11 |
| Low | 58.40 | 1 Week | -1.21 | -2.01 |
| Close | 58.96 | 1 Month | 9.21 | 18.51 |
| Volume | 2082331 | 1 Year | -4.41 | -6.96 |
| 52 Week High 65.28 | 52 Week Low 29.84 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| RXRX | 6.36 | -6.33% |
| BITF | 5.28 | -18.39% |
| PLUG | 3.48 | -9.61% |
| NVDA | 181.81 | 1.10% |
| ADAP | 0.20 | 11.11% |
| BYND | 0.52 | -22.39% |
| NVTS | 15.63 | 3.10% |
| LMDX | 0.02 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CYTK Daily Charts |
CYTK Intraday Charts |
Whats New @ Bazaartrend |
CYTK Free Analysis |
|
|
CYTK Important Levels Intraday
| RESISTANCE | 68.94 |
| RESISTANCE | 65.74 |
| RESISTANCE | 63.76 |
| RESISTANCE | 61.78 |
| SUPPORT | 56.14 |
| SUPPORT | 54.16 |
| SUPPORT | 52.18 |
| SUPPORT | 48.98 |
CYTK Forecast October 2025
| 4th UP Forecast | 87.33 |
| 3rd UP Forecast | 78.23 |
| 2nd UP Forecast | 72.61 |
| 1st UP Forecast | 66.98 |
| 1st DOWN Forecast | 50.94 |
| 2nd DOWN Forecast | 45.31 |
| 3rd DOWN Forecast | 39.69 |
| 4th DOWN Forecast | 30.59 |
CYTK Weekly Forecast
| 4th UP Forecast | 83.11 |
| 3rd UP Forecast | 75.36 |
| 2nd UP Forecast | 70.58 |
| 1st UP Forecast | 65.79 |
| 1st DOWN Forecast | 52.13 |
| 2nd DOWN Forecast | 47.34 |
| 3rd DOWN Forecast | 42.56 |
| 4th DOWN Forecast | 34.81 |
CYTK Forecast2025
| 4th UP Forecast | 134.36 |
| 3rd UP Forecast | 110.18 |
| 2nd UP Forecast | 95.23 |
| 1st UP Forecast | 80.29 |
| 1st DOWN Forecast | 37.63 |
| 2nd DOWN Forecast | 22.69 |
| 3rd DOWN Forecast | 7.74 |
| 4th DOWN Forecast | -16.44 |
Cytokinetics Incorporated ( NASDAQ USA Symbol : CYTK )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CYTK Business Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Address: 280 East Grand Avenue, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service